预防青春期少女和妇女宫颈癌前期的人乳头瘤病毒疫苗

Q3 Medicine International Journal of Evidence-Based Healthcare Pub Date : 2019-10-21 DOI:10.17267/2675-021xevidence.v1i2.2510

J. Li, Jessica Stetz

{"title":"预防青春期少女和妇女宫颈癌前期的人乳头瘤病毒疫苗","authors":"J. Li, Jessica Stetz","doi":"10.17267/2675-021xevidence.v1i2.2510","DOIUrl":null,"url":null,"abstract":"The evidence presented in this Cochrane meta-analysis shows the HPV vaccination confers significant benefit in preventing cervical pre-cancer. NNT of 60 for preventing one cervical pre-cancer (women 15 to 25 years old with or without HPV infection). The effect is higher for lesions associated with HPV16/18. The data also demonstrates an absence of serious adverse events. Therefore, we have assigned a color recommendation of Green (Benefit > Harm) to this vaccine.","PeriodicalId":55996,"journal":{"name":"International Journal of Evidence-Based Healthcare","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2019-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":"{\"title\":\"HPV vaccines for prevention of cervical pre-cancer in adolescent girls and women\",\"authors\":\"J. Li, Jessica Stetz\",\"doi\":\"10.17267/2675-021xevidence.v1i2.2510\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The evidence presented in this Cochrane meta-analysis shows the HPV vaccination confers significant benefit in preventing cervical pre-cancer. NNT of 60 for preventing one cervical pre-cancer (women 15 to 25 years old with or without HPV infection). The effect is higher for lesions associated with HPV16/18. The data also demonstrates an absence of serious adverse events. Therefore, we have assigned a color recommendation of Green (Benefit > Harm) to this vaccine.\",\"PeriodicalId\":55996,\"journal\":{\"name\":\"International Journal of Evidence-Based Healthcare\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-10-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Evidence-Based Healthcare\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.17267/2675-021xevidence.v1i2.2510\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Evidence-Based Healthcare","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17267/2675-021xevidence.v1i2.2510","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 2

摘要

Cochrane荟萃分析提供的证据显示，HPV疫苗接种对预防宫颈癌前期有显著益处。预防一名宫颈癌前病变(15至25岁感染或未感染HPV的妇女)的NNT为60。对于与HPV16/18相关的病变，效果更高。数据还表明没有发生严重的不良事件。因此，我们为该疫苗指定了绿色(益处>危害)的推荐颜色。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

HPV vaccines for prevention of cervical pre-cancer in adolescent girls and women

The evidence presented in this Cochrane meta-analysis shows the HPV vaccination confers significant benefit in preventing cervical pre-cancer. NNT of 60 for preventing one cervical pre-cancer (women 15 to 25 years old with or without HPV infection). The effect is higher for lesions associated with HPV16/18. The data also demonstrates an absence of serious adverse events. Therefore, we have assigned a color recommendation of Green (Benefit > Harm) to this vaccine.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

International Journal of Evidence-Based Healthcare Medicine-Health Policy

CiteScore

1.80

自引率

0.00%

发文量

期刊介绍： The International Journal of Evidence-Based Healthcare is the official journal of the Joanna Briggs Institute. It is a fully refereed journal that publishes manuscripts relating to evidence-based medicine and evidence-based practice. It publishes papers containing reliable evidence to assist health professionals in their evaluation and decision-making, and to inform health professionals, students and researchers of outcomes, debates and developments in evidence-based medicine and healthcare. The journal provides a unique home for publication of systematic reviews (quantitative, qualitative, mixed methods, economic, scoping and prevalence) and implementation projects including the synthesis, transfer and utilisation of evidence in clinical practice. Original scholarly work relating to the synthesis (translation science), transfer (distribution) and utilization (implementation science and evaluation) of evidence to inform multidisciplinary healthcare practice is considered for publication. The journal also publishes original scholarly commentary pieces relating to the generation and synthesis of evidence for practice and quality improvement, the use and evaluation of evidence in practice, and the process of conducting systematic reviews (methodology) which covers quantitative, qualitative, mixed methods, economic, scoping and prevalence methods. In addition, the journal’s content includes implementation projects including the transfer and utilisation of evidence in clinical practice as well as providing a forum for the debate of issues surrounding evidence-based healthcare.